Tech-enabled commercialization, medical & regulatory services partner to global biopharma firms.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 0 | 0 | 0 | 44 | 44 | 48 | 48 | 48 |
| Reserves | -105 | 324 | 764 | 1.0k | 1.4k | 2.6k | 2.8k | 3.1k |
| Borrowings | 483 | 51 | 66 | 502 | 490 | 102 | 122 | 144 |
| Other Liabilities | 222 | 220 | 524 | 638 | 627 | 609 | 588 | 1.3k |
| Total Liabilities | 600 | 596 | 1.4k | 2.2k | 2.5k | 3.3k | 3.6k | 4.6k |
| AssetsFixed Assets | 119 | 86 | 138 | 664 | 646 | 678 | 719 | 1.8k |
| CWIP | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 12 |
| Investments | 13 | 0 | 120 | 614 | 796 | 1.3k | 778 | 1.1k |
| Other Assets | 468 | 510 | 1.1k | 926 | 1.1k | 1.4k | 2.1k | 1.7k |
| Total Assets | 600 | 596 | 1.4k | 2.2k | 2.5k | 3.3k | 3.6k | 4.6k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (32.9×) and current (31.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 9.1% growth and a 32× exit, ₹532 only delivers your return if you pay ₹354. The price is currently baking in 17% growth.
EPS grows 9.1%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 9.1% | 18.21 |
| FY28 | 9.1% | 19.87 |
| FY29 | 9.1% | 21.67 |
| FY30 | 9.1% | 23.65 |
| FY31 | 9.1% | 25.80 |
| FY32 | 7.5% ·fade | 27.75 |
| FY33 | 6.0% ·fade | 29.41 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.